Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kiromic Biopharma Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KRBP
Over the counter
8731
https://kiromic.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kiromic Biopharma Inc
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
- Apr 24th, 2024 12:08 pm
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
- Apr 2nd, 2024 12:18 pm
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
- Mar 19th, 2024 12:08 pm
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
- Mar 8th, 2024 1:35 pm
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
- Mar 5th, 2024 1:35 pm
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
- Mar 1st, 2024 1:08 pm
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
- Feb 28th, 2024 11:30 pm
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
- Feb 14th, 2024 1:08 pm
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
- Jan 29th, 2024 12:47 pm
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
- Jan 5th, 2024 1:08 pm
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
- Dec 14th, 2023 1:17 pm
Kiromic BioPharma Announces Uplisting to OTCQB Market
- Nov 16th, 2023 9:36 pm
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
- Nov 9th, 2023 1:18 pm
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
- Oct 23rd, 2023 12:08 pm
Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
- Sep 13th, 2023 8:35 pm
Kiromic BioPharma Welcomes Two New Directors to its Board
- Jul 24th, 2023 7:00 pm
What's Going On With Kiromic BioPharma Stock Wednesday
- May 3rd, 2023 7:48 pm
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
- May 1st, 2023 12:08 pm
Scroll